Category Archives: New York Stem Cells

The 2nd Circuit Court of Appeals on Wednesday heard arguments in a case brought by a conservative nonprofit challenging a New York order that prohibits state health care workers from seeking religious exemptions to the COVID-19 vaccine mandate.

We The Patriots USA, Inc. wants the three-judge panel to grant a temporary injunction that would force the state to allow religious exemption requests from health care workers while the court fight continues.

The case stems from an emergency order issued in August by Democratic Gov. Kathleen Hochul requiring state health care workers to get a vaccine or a medical exemption or face suspension or termination. Over the weekend, she unveiled a plan to deal with potential worker shortages which includes the possibility of activating the National Guard.

The order took effect Monday, but a federal court in Utica last week ruled in a similar case and temporarily blocked the vaccine mandate for those seeking a religious exemption until Oct. 12 which prompted the circuit judges to question the need for another injunction.

Cameron Atkinson, lead attorney for the Connecticut-based nonprofit, argued the group of Christian nurses he represents should not be dependent on the outcome of other proceedings.

Theyre on a ticking clock, he said. As soon as that clock swings in the direction of the orders being lifted my clients are left hung out to dry theyre fired on the spot the next day.

The nurses say they do not want to take a vaccine linked to fetal stem cells because it would violate their Christian beliefs. They argue the lack of a religious exemption violates their First Amendment right to free exercise of religion.

Meanwhile, New York Deputy Solicitor General Steven Wu argued that the regulation does not run afoul of that constitutional right because it does not target or display hostility to religion and it applies to all health care workers.

Asked why there is a medical exemption but not a religious exemption, he said there was a desire to make it consistent with mandates for measles and rubella vaccines, which also only include medical exemptions. He added that religious exemptions generally exceed medical exemptions by a significant amount.

Mr. Wu said the governors order came in response to very serious concern over the highly transmissible delta variant which has really swamped the diagnoses that are taking place across the state.

And this order was issued to ensure the health care workers in these facilities who are dealing with particularly vulnerable populations will be protected themselves, and will not themselves be a vector for further spread in these facilities, he said.

It is not clear when the judges will rule on the case.

If the preliminary injunction is denied, We The Patriots USA, Inc. said it plans to file an emergency appeal to the U.S. Supreme Court.

The groups website states that it is dedicated to fighting to restore individual liberties and the God-given inalienable rights of all Americans, as recorded in the United States Constitution.

Continue reading here:
Court hears dispute over N.Y. healthcare workers seeking COVID vaccine religious exemption - Washington Times

This spring, Southwest Missouri folks thought the coronavirus was taking its last gasps, but it came back with a vengeance.

So, what happened? If we look back a year or so, we can see the beginnings of the reason.

COVID-19 news dominated the media, and ideas and opinions about how to protect ourselves swirled around us.

We eagerly soaked up information ranging from the reasonable to the ridiculous.

In this part of the world, Branson televangelist Jim Bakkers faithful followers received welcome news there was a cure for the threatening disease. A guest on the show assured believers that the product, Silver Solution, could totally eliminate the virus. Lucky viewers could buy a bottle of this magic COVID-19-killer for just $80 (NPR, March 11, 2020).

Bakkers remedy was a fraud and as part of a legal settlement he agreed to pay back at least $156,000 in restitution.

But, compared to Springfield-area health clinic owner and state Rep. Patricia Derges, R-Nixa, Bakker was a small fish.

Derges operated for-profit clinics in Springfield, Ozark and Branson and a nonprofit, Lift Up Someone Today, in Springfield.

Her clinics charged $167 each for COVID-19 tests, bringing in approximately $517,000. She is accused of fraudulently acquiring CARES Act funds through Lift Up by billing Greene County for tests that had already been paid for by other payers. She allegedly received $296,574, which she diverted to her for-profit Ozark Valley Medical Clinic.

Another major moneymaker was a regenerative stem-cell treatment that she is accused of advertising as a safe and natural potential cure for COVID-19. It didnt actually have any stem cells, according to prosecutors.

Derges was indicted on charges of felony wire fraud, illegal distribution of controlled substances, and making false statements. Her statehouse colleagues removed her from committee assignments in the state Capitol.

However, Chicago former osteopath Joseph Mercolas natural health operations make Bakker and Derges look like small fry. Mercola, a pioneer of the anti-vaccine movement, is the most influential spreader of COVID-19 misinformation online, researchers say.

In the last 10 years Mercola has built a vast operation that boosted his net worth to more than $100 million. He is listed as top man in the Disinformation Dozen, the group of 12 people responsible for sharing 65% of all anti-vaccine messaging on social media (The New York Times, July 25, 2021).

But theres an even larger fish in this propaganda sea, our longtime adversary: Russia.

It has weaponized COVID-19 misinformation in worldwide propaganda campaigns that push anti-vax messages on a large scale by using bots on troll farms and influencers recruited on Facebook. Reuters reported on Aug. 10 that Facebook had removed a network of accounts from Russia aimed at enlisting influencers to push anti-vaccine messaging.

Here in our corner of the world, these misleading campaigns have been overwhelmingly successful. Vaccination rates are low and more than 500 residents in the two-county Joplin metro area have lost their lives to the COVID-19 pandemic. On a recent weekend, 18 patients in Mercy and Freeman hospitals died.

The fallout from misinformation goes beyond the physical toll. The tsunami of divisive messaging has thrown our communities into chaos, torn relationships apart and caused menacing confrontations.

Were swimming in a sea of misinformation.

Lets try to avoid drowning in it.

Vera Nall lives in Neosho.

Read the original post:
Vera Nall: Misinformation will kill us in Southwest Missouri - Joplin Globe

The University of Texas at Dallas welcomed 25 new tenured and tenure-track faculty members in 2021, with many of them joining the University this fall.

The professors bring an array of expertise in disciplines ranging from visual and performing arts, psychology, and bioengineering to computer science, marketing, biological sciences and mathematics.

We are delighted to welcome this stellar group of professors to UT Dallas. They exemplify the Universitys strong tradition of research, scholarship and teaching excellence and will challenge our students to fulfill their potential, said UT Dallas President Richard C. Benson, the Eugene McDermott Distinguished University Chair of Leadership.

Recognized as a top-tier public research institution by the Carnegie Commission on Higher Education, UT Dallas is home to a growing roster of esteemed faculty who foster excellence in the classroom, forge community partnerships and attract exceptional students to the University. UT Dallas recently received a National Science Foundation grant to enhance its recruitment and retention of female professors in science, technology, engineering and mathematics.

UT Dallas is a top teaching and research destination, where students are learning from some of the best and brightest minds in their respective fields. This talented group is contributing to the rich environment of ideas found throughout our campus, said Dr. Inga Musselman, provost, vice president for academic affairs and the Cecil H. Green Distinguished Chair of Academic Leadership at UT Dallas.

The new tenured and tenure-track faculty members are:

The School of Arts and Humanities offers programs in visual and performing arts, history and philosophy, and literature and languages.

Dr. Laura Kim, assistant professor of visual and performing arts

Education: PhD in intermedia art, writing and performance, University of Colorado Boulder; Master of Fine Arts in new genres, San Francisco Art Institute; Bachelor of Science in art, University of Wisconsin-Madison

Research areas: performance-based multimedia, research in art

Dr. Maurine Ogbaa, assistant professor of literature

Education: PhD in literature, University of Houston; Master of Fine Arts in creative writing, Washington University in St. Louis; Bachelor of Arts in English language and literature, UT Austin

Research areas: contemporary African and African diasporic literature, particularly womens literature; theories of race, post/coloniality, historical materialism, and feminism and gender

Dr. Songyao Ren, assistant professor of philosophy and history of ideas

Education: PhD in philosophy, Duke University; Master of Arts in East Asian literatures and cultures, Columbia University; bachelors degree in journalism, The University of Hong Kong

Research areas: Chinese philosophy, ethics, moral psychology

Dr. Jerillyn Kent, assistant professor of psychology

Education: PhD in psychological and brain sciences, Indiana University Bloomington; Bachelor of Science in psychology and biology, William & Mary

Research areas: motor abnormalities in psychopathology, particularly cerebellar abnormalities in individuals with psychotic disorders; neuromodulation interventions for psychopathology

Dr. Waseem Abbas, assistant professor of systems engineering

Education: PhD and Master of Science in electrical and computer engineering, Georgia Institute of Technology; Bachelor of Science in electrical engineering, University of Engineering and Technology, Lahore, Pakistan

Research areas: networked control systems, cyber-physical systems, resilience and robustness in networked systems, distributed optimization, graph machine learning and graph-theoretic methods for multiagent systems

Dr. Shuang (Cynthia) Cui, assistant professor of mechanical engineering

Education: PhD in mechanical engineering, University of California, San Diego;Master of Science in thermal engineering and Bachelor of Science in energy systems and power engineering, Wuhan University

Research areas: advanced thermal energy storage materials and systems, intelligent soft materials and devices, nanoscale heat transfer and energy conversion, grid-interactive efficient buildings

Dr. Gu Eon Kang, assistant professor of bioengineering

Education: PhD in movement science and Master of Science in mechanical engineering and biomedical engineering, University of Michigan; Bachelor of Science in mechanical engineering, Korea University

Research areas: biomechanics, mobility research, frailty, diabetic foot, fall prevention, gait, posture, wearable sensors, motion analysis, computational modeling, finite element analysis, physical activity, physiological monitoring

Dr. Kyle McCall, assistant professor of materials science and engineering

Education: PhD in applied physics, Northwestern University; Bachelor of Science in physics and mathematics, University of Notre Dame

Research areas: materials chemistry, semiconductors for optoelectronics applications, halide perovskites, renewable energy conversion, light emission, radiation detection

Dr. Joshua Summers, professor and department head of mechanical engineering

Education: PhD in mechanical engineering, Arizona State University; Master of Science and Bachelor of Science in mechanical engineering, University of Missouri

Research areas: collaborative design, knowledge management, design enabler development with the overall objective of improving design through collaboration and computation

Dr. Yu Xiang, assistant professor of computer science

Education: PhD in electrical and computer engineering, University of Michigan; Master of Science and Bachelor of Science in computer science, Fudan University

Research areas: robotics, computer vision

The School of Economic, Political and Policy Sciences is home to eight academic programs, including criminology and criminal justice.

Dr. Anne M. Burton, assistant professor of economics

Education: PhD and Master of Arts in economics, Cornell University; Bachelor of Arts in economics and government, Colby College

Research areas: health economics, public economics, economics of crime

Dr. Sivaram Cheruvu, assistant professor of political science

Education: PhD and Master of Arts in political science, Emory University; Master of Science in politics and government in the European Union, The London School of Economics and Political Science; Bachelor of Arts in political science, Rutgers University

Research areas: comparative institutions, judicial decision-making, public law, European Union

Dr. Brenda Gambol, assistant professor of sociology

Education: PhD and Master of Philosophy in sociology, The City University of New York; Bachelor of Arts in ethnic studies and sociology, University of California, San Diego

Research areas: international migration, race and ethnicity, family and marriage

Dr. Jessica Hanson-DeFusco, assistant professor of public policy and political economy

Education: PhD in public policy and international development, University of Pittsburgh; Master of Education in international education policy, Harvard University; Bachelor of Arts in English-ESL secondary education, Colorado State University

Research areas: international development policies related to quality education, public health and gender rights

Dr. Andrew Krajewski, assistant professor of criminology and criminal justice

Education: PhD and Master of Arts in criminology, The Pennsylvania State University; Bachelor of Arts in psychology, University of South Florida

Research areas: verbal and physical aggression, interpersonal conflict, criminal behavior, social networks

Dr. Yeungjeom Lee, assistant professor of criminology and criminal justice

Education: PhD in criminology, law and society, University of Florida

Research areas: developmental life-course criminology, juvenile delinquency, victimization, psychopathy, substance use and crime

Dr. Lauren Pinson, assistant professor of public policy and political economy

Education: PhD, Master of Philosophy and Master of Arts in political science, Yale University; Master of Public Administration and Bachelor of Arts in international affairs, University of Georgia

Research areas: illicit trafficking, foreign aid, border security, migration

Dr. Allison Russell, assistant professor of public and nonprofit management

Education: PhD in social welfare, University of Pennsylvania; Master of Public Administration, University of North Carolina Wilmington; Bachelor of Arts in Latin American and Latino studies, Fordham University

Research areas: volunteerism, nonprofit human resources management, equity and ethics in nonprofits, social innovation and impact

Dr. Anton Sobolev, assistant professor of public policy, political economy, and cybersecurity

Education: PhD in political science and Master of Science in statistics, University of California, Los Angeles; Master of Arts in political economy and Bachelor of Arts in political science, Higher School of Economics University in Russia

Research areas: digital technology and political behavior, cybersecurity, misinformation, mass protest, text analysis

Dr. Samir Mamadehussene, assistant professor of marketing

Education: PhD in economics, Northwestern University; Master of Science in economics and Bachelor of Arts in management, Catholic University of Portugal in Lisbon.

Research areas: pricing and promotional strategies, game theory, consumer search

Dr. Nicholas Dillon, assistant professor of biological sciences

Education: PhD in microbiology and Master of Science in biology, University of Minnesota; Bachelor of Science in biochemistry, University of Wisconsin-Madison

Research areas: microbiology, antibiotic resistance, antibiotic pharmacology, host-pathogen interactions

Dr. Shengwang Du, professor of physics

Education: PhD in physics and Master of Science in electrical engineering, University of Colorado Boulder; Master of Science in physics, Peking University; Bachelor of Science in electrical engineering, Nanjing University

Research areas: quantum optics, quantum networks, quantum information processing, nonlinear optics, laser cooling and trapping, optical neural networks and artificial intelligence, optical microscopy, bioimaging

Dr. Purna Joshi, assistant professor of biological sciences

Education: PhD in stem cell biology, Master of Science in developmental biology and Bachelor of Science in pathobiology, University of Toronto

Research areas: stem cells, breast and ovarian cancer biology, regenerative medicine

Dr. Darshan Sapkota, assistant professor of biological sciences

Education: PhD in biochemistry and developmental neurobiology, The State University of New York at Buffalo; Master of Science in microbiology and Bachelor of Science, Tribhuvan University in Kathmandu, Nepal

Research areas: neuroscience, neurological diseases, regulation of mRNA translation, brain and retinal homeostasis, molecular biology

Dr. Yunan Wu, assistant professor of statistics

Education: PhD and Master of Science in statistics, University of Minnesota; Bachelor of Science in mathematics and physics, Tsinghua University in China

Research areas: causal inference in precision medicine, nonparametric and semi-parametric analysis, high-dimensional analysis, Mendelian randomization, machine-learning techniques

Read this article:
Meet the Newest Group of Tenured, Tenure-Track Faculty at UT Dallas - University of Texas at Dallas

Bench-to-bedside

Armed with this knowledge, further experiments showed that giving G-CSF, which is already used clinically as an immune system booster in cancer patients to mice with non-mutant IDH1 also increased their survival. And giving it in combination with the immune-stimulating gene therapy had an even bigger impact.

The team also confirmed that patients who have gliomas with mutated IDH1 also have higher levels of G-CSF circulating in their blood a clue that the findings will be applicable beyond the mouse models.

The next step, says Lowenstein, will be to work on moving these findings into a clinical trial, building on the current, ongoing trial using the immunotherapy/gene therapy combination.

Our study shows two main things: Patients with the IDH1 mutation may benefit from immunotherapy due to the G-CSF their tumors are producing, he said. And patients without the mutation may benefit from combining treatment with G-CSF and immunotherapy.

Additional authors include Brandon L. McClellan, Ruthvik P. Avvari, Rohit Thalla, Stephen Carney, Margaret S. Hartlage, Santiago Haase, Maria Ventosa, Ayman Taher, Neha Kamran, Li Zhang, Syed Mohammed Faisal, Felipe J. Nez, Mara Beln Garcia-Fabiani, Wajd N. Al-Holou, Daniel Orringer, Jason Heth, Parag G. Patil, Karen Eddy, Sofia D. Merajver, Peter J. Ulintz, Joshua Welch, Chao Gao, Jialin Liu and Gabriel Nez all of U-M; Shawn Hervey-Jumper of University of California, San Francisco; and Dolores Hambardzumyan of the Tisch Cancer Institute, Mount Sinai School of Medicine, New York.

Funding for the work was provided by National Institutes of Health and National Institute of Neurological Disorders & Stroke (R37-NS094804, R01-NS105556, R21- NS107894, R01- NS076991, R01-NS082311, R01-NS096756; the U-M Department of Neurosurgery; the Pediatric Brain Tumor Foundation, Leahs Happy Hearts Foundation, Ians Friends Foundation, Chad Tough Foundation, Pediatric Brain Tumor Foundation, and Smiles for Sophie Forever Foundation, National Cancer Institute (T32-CA009676), American Brain Tumor Association Basic Research Fellowship and a Rogel Cancer Center Scholar Award.

Paper cited: G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cells immunosuppression and enhances the efficacy of immunotherapy, Science Advances. DOI: 10.1126/sciadv.abh3243

See the original post here:
Glioma subtype may hold the secret to the success of immunotherapies - Michigan Medicine

Abstract: Global Stem Cell Banking Market to Reach US$11. 3 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Stem Cell Banking estimated at US$7.

New York, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Banking Industry" - https://www.reportlinker.com/p05799719/?utm_source=GNW 1 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.Placental and Cord Blood Stem Cells, one of the segments analyzed in the report, is projected to grow at a 7.4% CAGR to reach US$7.3 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adipose Tissue-Derived Stem Cells (ADSCS) segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 6.6% share of the global Stem Cell Banking market.

The U.S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 6.4% CAGR for the Period of 2020-2027

The Stem Cell Banking market in the U.S. is estimated at US$2.1 Billion in the year 2020. The country currently accounts for a 29.55% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$2 Billion in the year 2027 trailing a CAGR of 6.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR while Rest of European market (as defined in the study) will reach US$2 Billion by the year 2027.

Bone Marrow-Derived Stem Cells (BMSCS) Segment Corners a 10.3% Share in 2020

In the global Bone Marrow-Derived Stem Cells (BMSCS) segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$592.8 Million in the year 2020 will reach a projected size of US$858.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Select Competitors (Total 78 Featured)

Story continues

Cord Blood Registry

CordLife Group Ltd.

Cryo-Cell International, Inc.

Cryo-Save AG

Global Cord Blood Corporation

LifeCell International Pvt., Ltd.

Smart Cells International Ltd.

StemCyte Inc.

ViaCord

Vita 34 AG

Read the full report: https://www.reportlinker.com/p05799719/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Stem Cells, Application Areas, and the Different Types - A Prelude Applications of Stem Cells Types of Stem Cells Cord Blood Umbilical Cord Tissue Bone Marrow Stem Cells Adipose-Derived Stem Cells (ADSCs) Number of Clinical Trials Using Adipose Stem Cells: 2007-2018 Number of Adipose Stem Cell Trials by Phase: 2007 to 2018 Human Embryo-Derived Stem Cells (HESCS) Global Stem Cell Banking Market Poised for a Rapid Growth Developed Regions Lead, Emerging Economies to Spearhead Future Growth List of Family Cord Blood Banks in the US Placental and Cord Blood Banks Dominate the Cord Blood Banking Market Global Number of Annual Newborns and Private Cord Blood Banks Global Select Leading Cord Blood Banks Based on Inventory A Peek into China?s Cord Blood Banking Industry Evolving Landscape of Cord Blood Banking Industry Placental Stem Cells and Potential Clinical Applications EXHIBIT 1: Global Cord Blood Banking Market Share Breakdown (%) by Bank Type: 2019 EXHIBIT 2: US Cord Blood Banking Market by Bank Type (in %) for 2019 Changing Business Models for Stem Cell Banking

2. FOCUS ON SELECT PLAYERS Cord Blood Registry (CBR) Systems, Inc. (USA) Cordlife Group Limited (Singapore) Cryo Stemcell Private Limited (India) Cryo-Cell International, Inc. (USA) Cryoviva Biotech Private Limited (India) Global Cord Blood Corporation (China) LifeCell International Pvt. Ltd (India) Smart Cells International Ltd. (UK) StemCyte (USA) Takara Bio Europe AB (Europe) ViaCord (US) Vita34 AG (Germany)

3. MARKET TRENDS & DRIVERS Increasing Investments in Stem Cell-Based Research Widen Prospects for Stem Cell Banking Market EXHIBIT 3: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 Stem Cell Research Policies Impact Funding Volumes Adult Stem Cell Research Gains Traction, Accelerating Research Funding Adult Stem Cells Vs. Embryonic Stem Cells: A Comparison Embryonic Stem Cell Research Bogged Down by Ethical Issues & Technical Hurdles Induced Pluripotent Stem Cell (iPSC) Research: The Latest Vertical Sustained Emphasis on Mesenchymal Stem Cell Research Emergence of Advanced Technologies for Stem Cell Preservation, Storage and Processing Augurs Well for Market Growth Growing Incidence of Major Diseases to Boost the Demand for Stem Cells, Driving Stem Cell Banking EXHIBIT 4: Worldwide Incidence of Cancer (2012, 2018 & 2040): Number of New Cases Diagnosed Table 8: World Cancer Incidence by Cancer Type (2018): Number of New Cancer Cases Reported (in Thousands) for Breast, Cervix uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach and Others

Table 9: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others

Table 10: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) Ageing Demographics to Drive Demand for Stem Cell Banking Global Aging Population Statistics - Opportunity Indicators Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2017 & 2050)

Table 4: Global Aging Population (2017 & 2050): Population of 60+ Individuals in ?000s and as a Percentage of Total Population

Table 5: Life Expectancy for Select Countries in Number of Years: 2018 Bone Marrow Stem Cells Market on a Rapid Growth Path, Spurring the Need for Stem Cell Banking Development of Regenerative Medicine Accelerates Demand for Mesenchymal Stem Cell Banking Table 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell Banking Table 1: Global Orthopedic Surgical Procedure Volume (2010-2020) (in Million) Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Stem Cell Banking Rise in the Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion Hematopoietic Stem Cell Storage Dental Mesenchymal Stem Cells: An Evolving Niche Therapeutic Potential of Dental Pulp Stem Cells (DPSCs) in Various Diseases High Operational Costs of Stem Cell Banking - A Key Market Restraint

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for Placental and Cord Blood Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 4: World 7-Year Perspective for Placental and Cord Blood Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 5: World Current & Future Analysis for Adipose Tissue-Derived Stem Cells (ADSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 6: World 7-Year Perspective for Adipose Tissue-Derived Stem Cells (ADSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 7: World Current & Future Analysis for Bone Marrow-Derived Stem Cells (BMSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World 7-Year Perspective for Bone Marrow-Derived Stem Cells (BMSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Human Embryo-Derived Stem Cells (HESCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 10: World 7-Year Perspective for Human Embryo-Derived Stem Cells (HESCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 11: World Current & Future Analysis for Dental Pulp-Derived Stem Cells (DPSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 12: World 7-Year Perspective for Dental Pulp-Derived Stem Cells (DPSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 13: World Current & Future Analysis for Other Stem Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 14: World 7-Year Perspective for Other Stem Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 15: World Current & Future Analysis for Sample Preservation and Storage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 16: World 7-Year Perspective for Sample Preservation and Storage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 17: World Current & Future Analysis for Sample Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 18: World 7-Year Perspective for Sample Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 19: World Current & Future Analysis for Sample Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 20: World 7-Year Perspective for Sample Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 21: World Current & Future Analysis for Sample Collection and Transportation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 22: World 7-Year Perspective for Sample Collection and Transportation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 23: World Current & Future Analysis for Personalized Banking Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 24: World 7-Year Perspective for Personalized Banking Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 25: World Current & Future Analysis for Research Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 26: World 7-Year Perspective for Research Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 27: World Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 28: World 7-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Table 29: USA Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 30: USA 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 31: USA Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: USA 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 33: USA Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 34: USA 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027

CANADA Table 35: Canada Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 36: Canada 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 37: Canada Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 39: Canada Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 40: Canada 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027

JAPAN Table 41: Japan Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 42: Japan 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 43: Japan Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 45: Japan Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 46: Japan 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027

CHINA Table 47: China Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 48: China 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 49: China Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: China 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 51: China Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 52: China 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027

EUROPE Table 53: Europe Current & Future Analysis for Stem Cell Banking by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 54: Europe 7-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027

Table 55: Europe Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: Europe 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 57: Europe Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 58: Europe 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 59: Europe Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 60: Europe 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027

FRANCE Table 61: France Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: France 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 63: France Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 64: France 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 65: France Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 66: France 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027

GERMANY Table 67: Germany Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: Germany 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027

Table 69: Germany Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 70: Germany 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027

Table 71: Germany Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Continue reading here:
Global Stem Cell Banking Market to Reach US$11.3 Billion by the Year 2027 - Yahoo Finance

(Precision Vaccinations)

New York-based Regeneron Pharmaceuticals, Inc.announced that theU.S. Food and Drug Administration(FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV.

The FDA's EUAnow includes post-exposure prophylaxis in people at high risk for progression to severe COVID-19, who are not fully vaccinated or are not expected to mount an adequate response to vaccination, and have been exposed to a SARS-CoV-2 coronavirus infected individual, or who are at high risk of exposure to an infected individual because of infection occurring in the same institutional setting (such as in nursing homes or prisons).

Additionally, for those who require repeat dosing for ongoing exposure, REGEN-COV can also now be administered monthly.

This new indication in people aged 12 and older is in addition to the previously granted EUAto treatnon-hospitalized patients.

"Today's FDA authorization enables certain people at high risk ofdeveloping severe COVID-19 infectionto access REGEN-COV if they have beenexposedto the virus the first time an antibody treatment has been authorized for this purpose," statedGeorge D. Yancopoulos, M.D., Ph.D., President and CEOof Regeneron, in a press statement issued on July 30, 2021.

"With this authorization, the FDA specifically highlights the needs of immunocompromised people, including those taking immunosuppressive medicines, who may not mount an adequate response to (COVID-19) vaccination."

And "who are exposed to a person with COVID-19 or are in an institutional setting and are at high risk of exposure because of infection occurring in the same setting."

The "FDA decision to expand the use of REGEN-COV in post-exposure settings is a very helpful step, and we continue to work with the FDA as it undertakes its review of REGEN-COV in a broader group of people including in a pre-exposure prophylactic setting for people who are immunocompromised, and in patients hospitalized due to COVID-19."

Experts estimate that approximately 3% of theU.S.population may not respond fully to COVID-19 vaccination because of immunocompromising conditions or immunosuppressive medicines.

This group includespeople receiving chemotherapy, people with hematologic cancers such as chronic lymphocytic leukemia, people receiving stem cells or hemodialysis, people who have received organ transplants, and/or people taking certain medications that might blunt immune response (e.g., mycophenolate, rituximab, azathioprine, anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhibitors).

This new FDA EUAenables these groups to use REGEN-COV to prevent infection in post-exposure and certain institutional settings.

Under the EUA for post-exposure prophylaxis, REGEN-COV can be administered by subcutaneous injection or intravenous infusion.

For people who aren't expected to mount an adequate immune response to vaccination and have ongoing exposure to SARS-CoV-2 for more than four weeks, the initial 1,200 mg dose can be followed by subsequent repeat dosing of REGEN-COV 600 mg once every four weeks, for the duration of ongoing exposure.

Note:REGEN-COV is not a substitute for vaccination against COVID-19 and is not authorized for pre-exposure prophylaxis to prevent COVID-19. And the U.S. CDCdefines close contact as someone who has been withinsix feet of an infected person(laboratory-confirmed or aclinically compatible illness) for a cumulative total of 15 minutes or more over a 24-hour period.

Read the original:
COVID-19 Antibody Therapy Now Available For Treatment and Post-Exposure Prophylaxis - PrecisionVaccinations

DetailsCategory: Small MoleculesPublished on Wednesday, 04 August 2021 13:55Hits: 305

NEW YORK, NY, USA I August 04, 2021 I BeyondSpring (the Company or BeyondSpring) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, announced today the positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (n=559). Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. The data released today showed that compared to docetaxel alone, the combination met the primary endpoint of increasing overall survival (mean OS, p = 0.03; OS log rank, p <0.04) and met key secondary endpoints, including significantly improving ORR, PFS and 24- and 36-month OS rates, and significant reduction in the incidence of Grade 4 neutropenia.

The DUBLIN-3 Phase 3 trial is a randomized, single blind to patients, active controlled, global trial that enrolled 559 patients in 2nd and 3rd line NSCLC, EGFR wild type, with measurable lung lesion. Patients were treated on a 21-day cycle with infusion of docetaxel (75 mg/m2 on day 1) and plinabulin (30 mg/m2 on days 1 and 8) vs. docetaxel alone (75 mg/m2, day 1). The primary endpoint was overall survival. Plinabulin in combination with docetaxel (DP) showed statistically significant improvements compared to docetaxel alone (D) with topline data summarized below for ITT population (DP: n=278; D: n=281).

Trevor M. Feinstein, M.D., of the Piedmont Cancer Institute and a principal investigator for DUBLIN-3 commented, The treatment of 2nd and 3rd line NSCLC, especially with EGFR wild type where tyrosine kinase inhibitors do not work, is an area of severe unmet medical needs. Now that checkpoint inhibitor immunotherapy has moved into first line, there is a vacuum in this indication, where treatment is heavily centered around docetaxel. Currently, docetaxel-based therapies have limited survival benefit and >40% severe neutropenia. In DUBLIN-3, a prolonged survival benefit, characterized by a long-tailed OS curve, was observed with plinabulin that represents an immune associated anti-cancer benefit. The opportunity that plinabulin offers to these patients is not only to live longer, but also with significantly reduced severe neutropenia, which are both meaningful for these very sick patients.

Yan Sun, M.D., co-founder and former Chairman of Chinese Society of Clinical Oncology (CSCO), Chairman of NCCN Guidelines of NSCLC in China, and Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences added, DUBLIN-3 is a pivotal study which succeeded in demonstrating OS benefit for the first agent with a novel mechanism plinabulin since the 2015 nivolumab approval. It was very rewarding to be the global Principal Investigator throughout the 6 years for the DUBLIN-3 trial that serves to address this severe unmet medical need. In the DUBLIN-3 study, it is especially gratifying to see the doubling of 24- and 36-month OS rate with a favorable safety profile in the plinabulin combination arm; this profile not only significantly advances NSCLC patients care, but also signals plinabulins profound immune anti-cancer benefit. The success of the DUBLIN-3 study is the gateway of plinabulin into multiple tumor indications within IO combinations.

Dr. Ramon Mohanlal, CMO and EVP of R&D of BeyondSpring said, The success of the DUBLIN-3 study represents proof-of-concept of plinabulins immune-enhancing mechanism of action that is complimentary to that of checkpoint inhibitors, and which is the rationale for it to be combined as triple IO combinations in multiple tumor indications. These programs are already in Phase 1/2 stage and preliminary positive results were reported at ASCO 2021.

Dr. Lan Huang, BeyondSpring's co-founder, CEO and Chairwoman concluded, A pre-NDA meeting will be scheduled with the FDA in 2021 to agree on the contents for our NDA, to support a NSCLC indication NDA submission in the first half of 2022. This will be the second indication and second NDA for plinabulin. The superior benefit of plinabulin in reducing severe neutropenia of docetaxel in DUBLIN-3 further supports our first NDA submission in CIN prevention, which received FDA priority review with a PDUFA date of November 30, 2021. Importantly, the strong results from DUBLIN-3 further validate our conviction that plinabulin, as an immune anti-cancer agent, has the potential to be a cornerstone therapy for many solid tumors. I'd like to take the time to thank everyone who helped make this 6-year study run smoothly at more than 60 sites across the U.S., China and Australia, including all participating patients and their families, the investigators and clinical staff and the dedicated BeyondSpring team.

Conference Call and Webcast InformationBeyondSprings management will host a conference call and webcast today at 8:30 a.m. Eastern Time. The dial-in numbers for the conference call are 1-877-451-6152 (U.S.) or 1-201-389-0879 (international). Please reference conference ID: 13722298. A live webcast will be available on BeyondSprings website atwww.beyondspringpharma.comunderEvents & Presentationsin the Investors section. An archived replay of the webcast will be available for 30 days.

About PlinabulinPlinabulin, BeyondSprings lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. It is a novel, intravenous infused, patent-protected, NDA stage asset for CIN prevention and a Phase 3 anti-cancer candidate for non-small cell lung cancer (NSCLC). Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells, and the second is early-onset of action in CIN prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs). Plinabulin received Breakthrough Therapy designation from both U.S. and China FDA for the CIN prevention indication. As a pipeline in a drug, plinabulin is being broadly studied in combination with various immuno-oncology agents that could boost the effects of the PD-1/PD-L1 antibodies and re-sensitize PD-1/PD-L1 antibody-resistant patients.

About BeyondSpringHeadquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSprings first-in-class lead asset plinabulin, is being developed as a pipeline in a drug. It is filed for approval and has received Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) with a PDUFA date of November 30, 2021 in the U.S., and has a fully enrolled pivotal study (DUBLIN-3) to test an anti-cancer benefit with an overall survival primary endpoint in NSCLC. Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

SOURCE: BeyondSpring

See the original post here:
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment...

Primary Cells Market Research Report by Origin (Animal Primary Cells and Human Primary Cells), by Cell Type (Dermatocytes, Gastrointestinal Cells, and Heart Cells), by End-user, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

New York, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06087175/?utm_source=GNW

The Global Primary Cells Market size was estimated at USD 1,025.78 Million in 2020 and expected to reach USD 1,144.46 Million in 2021, at a Compound Annual Growth Rate (CAGR) 11.90% from 2020 to 2026 to reach USD 2,014.78 Million by 2026.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Primary Cells to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Origin, the Primary Cells Market was studied across Animal Primary Cells and Human Primary Cells.

Based on Cell Type, the Primary Cells Market was studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.

Based on End-user, the Primary Cells Market was studied across Life Science Companies and Research Institutes.

Based on Geography, the Primary Cells Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Primary Cells Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Primary Cells Market, including AcceGen, Allcells, American Type Culture Collection, Axol Bioscience Ltd., BioIVT, Biopredic International, BPS Bioscience, Inc., Cell Biologics, Inc., Corning Incorporated, Creative Bioarray, Epithelix SRL, Ixcells Biotechnologies, Lonza Group AG, Merck KGaA, Neuromics, Ppa Research Group, Inc., Promocell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Primary Cells Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Primary Cells Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Primary Cells Market?4. What is the competitive strategic window for opportunities in the Global Primary Cells Market?5. What are the technology trends and regulatory frameworks in the Global Primary Cells Market?6. What is the market share of the leading vendors in the Global Primary Cells Market?7. What modes and strategic moves are considered suitable for entering the Global Primary Cells Market?Read the full report: https://www.reportlinker.com/p06087175/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See more here:
Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo...

Though IPO activity typically slows down in the summer months, this summer has been atypical. The public markets continue to welcome new companies at a breakneck pace, and healthcare is well represented. Of the 20 companies that went public in the last week, 11 of them are doing work in some aspect of the life sciences.

Five of these newly public companies are developing new cancer treatments. Rare disease and heart disease are represented as well. But the biggest biotech IPO belongs to a clinical-stage company that is making progress with vaccine candidates offering the potential to address variants of SARS-CoV-2. According to IPO research firm Renaissance Capital, the 20 IPOs make up the biggest IPO total for a single week since 2000. However, Bill Smith, CEO and co-founder of Renaissance, said this level of activity comes at a price.

Simply put, investors are tired, he wrote in the firms newsletter published on Sunday. Combine that fatigue with increased pricing pressure, and performance starts to suffer. Three companies postponed, citing either volatility or market conditions. Of the IPOs that did get done, nearly half priced below the midpoint, and returns were a mixed bag.

IPO activity might take a break for August. Renaissance notes that new filings have slowed in the runup to these dog days of summer. Heres a recap of the weeks IPO activity from the life sciences side, mixed bag and all.

Icosavax reels in $182M for clinical trials of its VLP vaccines

Vaccine developer Icosavax had the biggest life sciences IPO of the week, raising $182 million. After initially planning to offer 11.5 million shares in the range of $14 to $16 each, the company was able to boost the deals size to 12.1 million shares priced at the midpoint of the targeted price range. Icosavax shares trade on the Nasdaq under the stock symbol ICVX. On the companys first day of trading Thursday, the stock price more than doubled. Shares closed Friday at $34.97, up more than 133% from the IPO price.

Seattle-based Icosavax produces vaccines by engineering proteins into virus-like particles. These particles contain no genetic material but resemble a virus closely enough to elicit an immune response. Lead Icosavax vaccine candidate IVX-121 has reached Phase 1 testing in respiratory syncytial virus (RSV). That vaccine is also part of an experimental bivalent vaccine called IVX-A12, which is comprised of the RSV candidate along with a candidate for human metapneumovirus (hMPV), which is another respiratory virus. Icosavax has also used its VLP platform to develop a SARS-CoV-2 vaccine candidate, IVX-411.

Icosavax plans to spend $120 million to take its bivalent RSV/hMPV vaccine into Phase 2b testing, according to the prospectus. Another $35 million will go toward the development of other vaccines, including advancing the Covid-19 vaccine candidate through Phase 1/2 and Phase 2 testing.

Candel cuts deal size, raises $72M for oncolytic viruses

Candel Therapeutics raised $72 million for its cancer drugs, but it had to shrink the size of the deal to go public. The biotech initially planned to offer more than 6 million shares in the range of $13 to $15 per share. Candel ended up selling 9 million shares for $8 apiece. Those shares trade on the Nasdaq under the stock symbol CADL.

Needham, Massachusetts-based Candel is developing oncolytic viral therapies, engineered viruses that kill cancer cells. It has two technology platforms, one using a genetically modified adenovirus and the other based on herpes simplex virus. The adenovirus platform has produced Candels most advanced therapeutic candidate, CAN-2409, which is currently in Phase 3 testing in newly diagnosed prostate cancer. According to the IPO filing, the company expects to complete enrollment in the third quarter of this year and report final data in 2024. A separate Phase 3 study testing CAN-2409 in newly diagnosed high-grade glioma is expected to start in the first half of next year. The most advanced program from the herpes simplex virus platform, CAN-3110, is in Phase 1 testing in recurrent high-grade glioma. The IPO cash will go toward clinical trials, including the construction of a manufacturing facility to produce its oncolytic viruses for those studies.

Rare disease biotech Rallybio raises $80.6M from IPO

Rallybio, a clinical-stage developer of therapies for rare diseases, raised $80.6 million from its IPO. The New Haven, Connecticut-based company planned to offer 5.75 million shares. The company ended up selling 6.2 million shares for $13 each, the low end of the $13 to $15 price range it had set. Rallybio shares trade on the Nasdaq under the stock symbol RLYB.

The most advanced Rallybio program is RLYB211, a polyclonal antibody in development to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). The rare and potentially life-threatening blood disorder develops when platelets of a pregnant woman have a surface protein that the platelets of the fetus see as foreign, sparking antibodies to the protein. The Rallybio lead therapy is in Phase 1/2 testing. According to the prospectus, the company plans to spend $75 million to $83 million to complete the clinical trial. That cash will also support completion of Phase 1 tests of RLYB212, a monoclonal antibody for FNAIT.

IPO brings $166M in new cash for Nuvalents cancer drugs

Nuvalents IPO raised $165.75 million to advance its cancer drugs to clinical trials. The Cambridge, Massachusetts-based biotech planned to offer 8.9 million shares in the range of $16 to $18 each. The company was able to boost the size of the deal to 9.75 million shares priced at the midpoint of the projected price range. Those share trade on the Nasdaq under the stock symbol NUVL.

Nuvalent is developing small molecule kinase inhibitors. While drugs from this class have already been approved to treat cancer, the company said in its IPO filing that it designs its small molecules to overcome drug resistance, adverse events, the ability to penetrate into the brain, and other limitations to currently available kinase inhibitors. The companys two lead programs target cancers driven by genomic alterations in the ROS1 and ALK kinases. According to the IPO filing, between $60 million and $65 million is earmarked for NVL-520, which is being readied for the Phase 1 part of a Phase 1/2 study in ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. Another $55 million to $60 million is set aside for NVL-655, which is on track to advance to the Phase 1 portion of a Phase 1/2 study in ALK-positive NSCLC and other advanced cancers.

Omega Therapeutics pulls in $126M for programmable drugs

Omega Therapeutics is developing drugs that act on genes. But rather than turning them on or off, the companys drugs, which it calls epigenomic controllers, are more like a dimmer switch that can dial a genes activity up or down. The companys drugs are comprised of messenger RNA encapsulated in a lipid nanoparticle. The company says its approach has potentially applications in regenerative medicine and immunology but cancer is the first target. Lead program OTX-2002 is being developed to down-regulate c-Myc, a gene frequently dysregulated in cancer.

Cambridge-based Omega priced its offering of 7.4 million shares at $17 each, which was the midpoint of its targeted price range. The company raised $125.8 million to apply to its drug pipeline. According to the IPO filing, the company plans to file the paperwork to begin clinical trials in 2022, evaluating an epigenomic controller as a treatment for liver cancer. Omegas shares trade on the Nasdaq under the stock symbol OMGA.

Tenaya Therapeutics takes in $180M for heart drug R&D

In a crowded field of newly public cancer drug developers, the heart disease focus of Tenaya Therapeutics stands out. But this focus gives it a large addressable market. Heart disease is the leading cause of death worldwide, the company points out in its IPO filing.

San Francisco-based Tenaya aims to treat heart disease with gene therapies, biologics, and small molecules. The companys most advanced gene therapy program, TN-201, is being prepared for clinical testing as a treatment for hypertrophic cardiomyopathy caused by genetic mutations. The gene therapy is designed to deliver a fully functional version of the mutated gene. The pipeline also includes a small molecule, TYA-11631, with potential applications in heart failure and genetic dilated cardiomyopathy.

Tenaya planned to offer 10 million shares in the range of $14 to $16 each. But the preclinical biotech found enough investor interest to boost the offering to 12 million shares priced at the midpoint of the targeted price range, raising $180 million. The biotechs shares trade on the Nasdaq under the stock symbol TNYA. According to Tenayas IPO filing, the company plans to spend $35 million to $40 million on its lead gene therapy and $10 million to $15 million on its lead small molecule, including the planned start of Phase 1/2 testing for both programs.

Immuneerings IPO raises $112M for a better MEK inhibitor

Immuneerings IPO raised $112.5 million to bring its lead cancer drug candidate into clinical testing. That program, IMM-1-104, is type of cancer drug called a MEK inhibitor. Other MEK inhibitors have been approved by the FDA previously, but the biotech says in its prospectus that its drug has features that enable it to avoid drug resistance while improving its tolerability. Immuneering expects to file the investigational new drug application paperwork in the first quarter of 2022, with plans to begin a Phase 1 study in patients with advanced solid tumors characterized by RAS mutations.

Cambridge-based Immuneering offered 7.5 million shares at $15 apiece, which was the midpoint of the projected price range. The company plans to spend between $33 million and $38 million on its lead program; $38 million to $43 million is budgeted for research on its other preclinical programs. The companys shares trade on the Nasdaq under the stock symbol IMRX.

Cancer biotech In8bio prices $40M IPO below targeted price range

IN8bio, a clinical-stage company developing cell therapies for cancer, raised $40 million in its stock market debut. The biotech offered 4 million shares for $8 each, well below the $10 to $12 per share range it had planned. IN8Bio shares trade on the Nasdaq under the stock symbol INAB.

New York-based IN8bio is developing cell therapies from gamma-delta T cells, which are immune cells that have properties of both the innate and adaptive immune systems. The company said in its IPO filing that these cells can differentiate between healthy and diseased tissue and may kill tumors directly, and also recruit and direct immune cells to kill tumors as well. Lead therapeutic candidate INB-200 is in Phase 1 testing in newly diagnosed glioblastoma; INB-100 is in early-stage testing for treating leukemia patients who are undergoing stem cell transplants. The biotech plans to apply the IPO proceeds toward its ongoing clinical research.

RxSights IPO raises $117M for intraocular lens technology

RxSight stands apart from most of this group of newly public life science companies in that it has reached the commercial stage. The RxSight Light Adjustable Lens is an implantable intraocular lens that can be adjusted after surgery. The product is intended to offer better visual outcomes compared to cataract surgeries that replace the lens with one that is not adjustable after the surgery. The FDA approved the RxSight technology in 2017; it also has marketing authorization in Europe and Mexico. The company reported $14.6 million in 2020 sales, a 554% increase over the prior year, according to the prospectus.

Aliso Viejo, California-based RxSight priced its offering of 7.35 million shares at $16 per share, raising $117.6 million. The company plans to spend $40 million to support commercialization of its product and $44 million on product development, research, and clinical development. RxSights shares trade on the Nasdaq under the stock symbol RXST.

MaxCyte rides the cell therapy R&D wave to a $175M IPO

MaxCyte, a company that already trades on the London stock exchange operated AIM, raised $175.5 million in its U.S. stock market debut. The company initially planned to offer more than 12 million shares in the range of $11.50 and $13.50 per share. It was able to boost the deal size, selling 13.5 million shares for $13 apiece, raising $175.5 million. On the Nasdaq, MaxCyte now trades under the stock symbol MXCT.

Gaithersburg, Maryland-based MaxCyte has commercialized a proprietary flow electroporation technology, which is used in the engineering of a wide variety of cells for cell therapies. The companys customers include cell therapy developers, large biopharmaceutical companies, and government and academic institutions. MaxCyte reported $26.1 million in revenue in 2020, a 21% increase over 2019 sales, according to the IPO filing. MaxCyte plans to spend $20 million to $30 million on R&D, including commercialization of its VLX system, which is designed for extremely large volume cell engineering. Another $20 million to $30 million is set aside for manufacturing; and $10 million to $20 million on sales and marketing and business development.

Drug/device company Rani Therapeutics reels in $73M for oral biologics

One of the reasons that biologic drugs come in an injectable and not oral formulations is that these large molecules cant survive the digestive environment. Rani Therapeutics is developing a capsule that carries a biologic payload that withstands stomach acid, then, in the upper half of the small intestine, dissolves and exposes a microneedle that injects the drug into the intestinal wall.

San Jose, California-based Rani plans to develop its RaniPill for oral delivery of biologic drugs that are already approved and have been available for years only in injectable form. Phase 1 tests have been completed. Rani said in its IPO filing that it plans to meet with the FDA in the second half of this year to discuss its drug pipeline. Ranis IPO raised $73 million. The company priced its offering of 6.7 million shares at $11 each, well below the $14 to $16 per share range it projected. Rani shares trade on the Nasdaq under the stock symbol RANI.

Photo by Getty Images

Original post:
5 days, 11 life science IPOs & more than $1.3B in new capital - MedCity News

VioletaStoimenova/Getty

Im severely anemic. Hence, I have approximately the same skin tone as the Vampire Lestat. Its sort of punk rock/goth-y, so it doesnt bother me. But I also get so tiredthat I nap almost every afternoon, and thats decidedlynot punk rock. That fatigue is brutal: Ive cried because I couldnt walk up a mountain Id traipsed up before. Those are traditional signs of iron deficiency anemia. Most people know them. But there are plenty of signs youve probably never heard of.

You probably know anemia comes in several flavors: sickle-cell anemia, which is inherited and has to do with the shape of the red blood cells, for example. But the Mayo Clinic explains that there are more: Thalassemia, another inherited blood disorder, when your red blood cells dontmakeenough hemoglobin; aplastic anemia, when your body simply stops producing new red blood cells; vitamin deficiency anemia, which happens when you dont get enough Vitamin B-12, Vitamin C, and folate; and iron deficiency anemia, which occurs when you simply dont ingest enough iron.

I have iron deficiency anemia.

According to Hematology.org, anemia is the most common blood disorder. One study by the National Health and Nutrition Examination Survey found that 11%, or 3.3 million American women, have iron deficiency anemia. It happens, simply, when your body doesnt have enough red blood cells. Biology 101 flashback: red blood cells, the Mayo Clinic explains, contain hemoglobin. Thats the stuff that makes blood red. Hemoglobin lets blood cells carry oxygen from the lungs to the body, and carbon dioxide from the body back to the lungs.

Your body needs iron to make red blood cells.

Iron deficiency anemia means, simply, that your body doesnt have enough iron to make an adequate number of blood cells. It happens in a lot of pregnant people, and it can also happen from heavy periods.

But iron deficiency anemia often causesheavy periods, too, as Jacques Moritz, MD, director of gynecology at Mount Sinai St. Lukes Roosevelt in New York City told Health.com, They lose too much blood, replace about half of it, and then lose too much again the following month. Its like filling up a car with a small hold in the tank.

It can also happen simply because you dont ingest enough iron.

Ive always gotten heavy periods. And I really, really suck at ingesting iron.

I hate meat. I came into this world hating meat, and Ill eat some of it (bacon, occasionally chicken, steak or pulled pork BBQ), but generally, Im a vegetarian. And I dont eat seafood either (other than oysters). Last week, I ate meat once: I scavenged my kids chicken tenders.

Then I bled half of my iron out again. My periods are bad enough that if I was immediately postpartum, Id send ER docs running, not walking. Think the worst period youve ever had. Multiply it. Think multiple layers of period protection. Think days when I cant leave the house.

Three months ago, because of my Lestat-like complexion and severe fatigue, coupled with dark lines at the tops of my fingernails and cracks at the corners of my mouth (both signs of a vitamin deficiency, usually iron), my primary care doc drew my blood and eyeballed my hemoglobin values. Normal levels for a woman are 12 grams per deciliter, according to Hematology.org. My hemoglobin value was an eight. I wasmissing a third of my red blood cells.

My doctor looked at me and said, Look. I can refer you to a hematologist now. Theyll give you iron infusions. I had severe iron deficiency anemia during my last pregnancy and received iron infusions: twice a week I drove to a clinic where they stuck a needle in my arm and dripped iron into me for three hours while I played on my phone. It didnt bother me much until the next day, when my entire skeleton hurt. Every. Single. Bone. Ached. For like, two days. Then I had a good day. Then I had another freaking infusion.

I did not want infusions.

So I begged for three months.Look, if we cant get them up, Ill take the referral then. Please, please, please.He agreed to give me three months and sent me home with some medical-grade iron pills.

Real talk: I could not have averted this with over-the-counter iron pills. I cant take them. They do things to my digestive system. The kind of things that necessitate lots of prunes and Miralax and Metamucil, and all that still doesnt work.

Some of my problems with iron probably stem from disordered eating left over from anorexia: I generally eat one full meal a day. I dont freak about the calories in it, but I hardly snack; I never liked breakfast; and I dont get hungry for lunch.

My husband knew two more meals a day was probably a losing battle, because I wasnt going to eat a substantial breakfast, and I legitimately forget about lunch (that happens when youdont get hungry). So he concocted a chili recipe involving pureed iron-rich greens, a ton of legumes, and lots of veggies. Basically, its a superfood. And as long as Ilikesomething, Ill eat it every goddamn day, because I dont have to think about it (my ADHD gives me choice paralysis: I cant make a simple decision and freak out. This usually happens at dinnertime). And no, you cant taste the spinach.

So I eat chili. I eata lotof chili. I also eat a lot of chickpea pasta, which contains about half of your daily iron needs.

But clearly this isnt enough to defeat iron-deficiency anemia, so I have to take pills and drink a vitamin supplement called Floradix. It doesnt taste great, and I throw it down like a frat boy.

But when I went in three months later, despite three hellish periods, my iron levels had gone up to a 9.5. So Im only missing a little less than a quarter of my blood cells now.Moral: never underestimate the power of chili.

Ill have to keep this up. If I dont, my levels willdrop again. So hello, life of supplements and chili. Youll be with me forever. But at least I wont sleep for four hours every day, and I look a little less vampire and a little more standard goth.

And at least I really, really like that chili.

The rest is here:
What Its Like To Have Severe Iron Deficiency Anemia - Scary Mommy